

In re: Gawad et al.  
 Serial No. to be assigned  
 Filed: concurrently herewith  
 Page 7

(a) simultaneously contacting the sample with a first antibody which binds selectively to multimeric vitronectin, the first antibody being [immobilised] ~~immobilized~~ on a solid support, and with a labelled second antibody which binds selectively to PAI-1; and

(b) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

9. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample with a first antibody which binds selectively to multimeric vitronectin, the first antibody being [immobilised] ~~immobilized~~ on a solid support;

(b) contacting the solid support with a labelled second antibody which binds selectively to PAI-1; and

(c) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

10. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample with a first antibody which binds selectively to PAI-1, the first antibody being [immobilised] ~~immobilized~~ on a solid support;

(b) contacting the solid support with a second antibody which binds selectively to multimeric vitronectin;

(c) contacting the solid support with a labelled third antibody which binds selectively to the second antibody; and

(d) determining the third antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

11. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample with a first antibody which binds selectively to multimeric vitronectin, the first antibody being [immobilised] ~~immobilized~~ on a solid support;

(b) contacting the solid support with a second antibody which binds s

In re: Gawad et al.  
Serial No. to be assigned  
Filed: concurrently herewith  
Page 8

selectively to PAI-1;

(c) contacting the solid support with a labelled third antibody which binds selectively to the second antibody; and

(d) determining the third antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

12. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample, either simultaneously or stepwise, with a first antibody which binds selectively to PAI-1 and to which is attached one member of a capture pair and with a labelled second antibody which binds selectively to multimeric vitronectin to form a mixture;

(b) contacting the mixture with a solid support on which is [immobilised] immobilized the other member of the capture pair; and

(c) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

13. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample either simultaneously or stepwise, with a first antibody which binds selectively to multimeric vitronectin and to which is attached one member of a capture pair and with a labelled second antibody which binds selectively to PAI-1 to form a mixture;

(b) contacting the mixture with a solid support on which is [immobilised] immobilized the other member of the capture pair; and

(c) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

14. (Amended) The method [of any one of claims] according to claim 1 [to 13] wherein the biological fluid is selected from the group consisting of whole blood, plasma, serum, urine, saliva, amniotic fluid, cerebrospinal fluid and a tissue extract.

In re: Gawad et al.  
Serial No. to be assigned  
Filed: concurrently herewith  
Page 9

15. (Amended) The method [of any one of claims to 13] according to claim 1 wherein the biological fluid is whole blood, plasma or serum.

16. (Amended) The method [of any one of the preceding claims] according to claim 1 wherein the second antibody is labelled with a directly detectable label.

17. (Amended) The method [of any one of the preceding claims] according to claim 1 wherein the second antibody is labelled with a component of a signal-generating system.

19. (Amended) The method [of any one of claims] according to claim 1 [to 15] wherein the second antibody is labelled with a fluorophore.

23. (Amended) The method of [any one of claims] claim 1 [to 15] wherein the second antibody is labelled with a label selected from the group consisting of a metal complex, a stable free radical, a vesicle, a liposome, a colloidal particle, a latex particle, a spin label and biotin/avidin.

27. (Amended) The kit of claim 25 [or 26] wherein said first antibody is [immobilised] immobilized on a solid support.

28. (Amended) The kit of [any one of claims] claim 25 [to 27] further comprising a set of calibration standards.

30. (Amended) The kit of claim 29 wherein said first antibody is [immobilised] immobilized on a solid support.

31. (Amended) The kit of claim 29 [or 30] further comprising a set of calibration is standards.

33. (New) The kit of claim 26 further comprising a set of calibration standards.